Pfizer seeds diabetes upstart AnTolRx with cash and an option deal
Pfizer is backing a newly minted biotech that is right at the very earliest stage of taking an academic program out of a Harvard lab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
